Oruka Therapeutics Q2 FY26 net loss widens to $41.2 million; R&D expenses rise to $43.3 million
ORKA•Cash position and pipeline timeline
Cash, cash equivalents and marketable securities totaled $1.1 billion as of June 30, 2026, and the company said that amount is expected to fund operations through a planned ORKA-001 BLA filing.
EVERLAST-A Week 28 data are due at the end of 3Q 2026. EVERLAST-B had enrolled 187 patients, with Week 16 data expected in 4Q 2026 to support a Phase 3 start in 1H 2027.
Q2 loss widens as R&D spending rises
Oruka Therapeutics posted a Q2 2026 net loss of $41.2 million, widening from $24.6 million a year earlier.
R&D expenses climbed to $43.3 million from $24.1 million, driven by added trials, a Halozyme upfront payment and higher compensation.
G&A expenses rose to $6.9 million from , while other income increased to from on higher interest.
